“…More recently, it was reported that sensitized TCs require different DS regimens to reduce DSA levels, including varying the IVIG dose and the number of PP cycles Thielke et al, 2005;Ferrari-Lacraz et al, 2006;Glotz et al, 2004;Rogers et al, 2011). Subsequent studies have demonstrated that susceptibility to IVIG/PP DS depends on immunoregulatory mechanisms, such as polymorphisms in cytokine genes, the frequency of regulatory cells, and hormonal backgrounds (Figure 7) (Glotz et al, 2004;Rogers et al, 2011;Zachary et al, 2003;Bas et al, 1998;Di Genova et al, 2006, 2010Jiang & Lechler, 2003, Amu et al, 2007Anderson et al, 2000;Hill & Sarvetnick, 2002;Kalil et al, 1989;Stasi et al, 2008;Stastny P et al, 2006;Yoo et al, 1995). Furthermore, the efficacy of DS has been reported to be different for DSAs and third-party HLA antibodies.…”